Literature DB >> 11839700

Molecular testing for antibiotic resistance in Helicobacter pylori.

R J Owen1.   

Abstract

An estimated 7.5 million individuals in England and Wales are actively infected with Helicobacter pylori and hence knowledge of local resistance rates is of growing importance. Also, information on strain resistance following treatment failure is crucial in selecting an appropriate regimen as the development of bacterial resistance to antibiotics makes retreatment difficult. Molecular test methods may have an impact on improving the availability and accuracy of information on H pylori antimicrobial resistance to guide in the selection of primary as well as secondary backup treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839700      PMCID: PMC1773144          DOI: 10.1136/gut.50.3.285

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  44 in total

1.  Antagonist: should we eradicate Helicobacter pylori in non-ulcer dyspepsia?

Authors:  D Pantoflickova; A L Blum
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Rapid molecular identification and subtyping of Helicobacter pylori by pyrosequencing of the 16S rDNA variable V1 and V3 regions.

Authors:  H Monstein; S Nikpour-Badr; J Jonasson
Journal:  FEMS Microbiol Lett       Date:  2001-05-15       Impact factor: 2.742

3.  Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay.

Authors:  S Maeda; H Yoshida; H Matsunaga; K Ogura; O Kawamata; Y Shiratori; M Omata
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis.

Authors:  M J Torres; A Criado; J C Palomares; J Aznar
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori.

Authors:  D H Kwon; F A El-Zaatari; M Kato; M S Osato; R Reddy; Y Yamaoka; D Y Graham
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis.

Authors:  E J van der Wouden; J C Thijs; A A van Zwet; W J Sluiter; J H Kleibeuker
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

7.  The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori.

Authors:  P J Jenks; R L Ferrero; A Labigne
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

8.  Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens.

Authors:  A Marais; L Monteiro; A Occhialini; M Pina; H Lamouliatte; F Mégraud
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

9.  Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.

Authors:  M P Dore; G Leandro; G Realdi; A R Sepulveda; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

10.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Authors:  J Versalovic; D Shortridge; K Kibler; M V Griffy; J Beyer; R K Flamm; S K Tanaka; D Y Graham; M F Go
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more
  17 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 2.  Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy.

Authors:  Ozlem Yilmaz; Ebru Demiray
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

3.  Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

4.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

Review 5.  A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.

Authors:  Elvira Garza-González; Guillermo Ignacio Perez-Perez; Héctor Jesús Maldonado-Garza; Francisco Javier Bosques-Padilla
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 6.  Helicobacter pylori-Associated Diseases.

Authors:  Michael K Sanders; David A Peura
Journal:  Curr Gastroenterol Rep       Date:  2002-12

7.  Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H. pylori isolates from gastric biopsy specimens by real-time PCR.

Authors:  Christine Lascols; Dominique Lamarque; Jean-Marc Costa; Christiane Copie-Bergman; Jeanne-Marie Le Glaunec; Lionel Deforges; Claude-James Soussy; Jean-Claude Petit; Jean-Charles Delchier; Jacques Tankovic
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

Review 8.  Helicobacter pylori detection and antimicrobial susceptibility testing.

Authors:  Francis Mégraud; Philippe Lehours
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

9.  Detection of primary clarithromycin resistance of Helicobacter pylori and association between cagA (+) status and clinical outcome.

Authors:  Erkan Yula; Toğrul Nagiyev; Ozlem Aycan Kaya; Melek Inci; M Murat Celik; Fatih Köksal
Journal:  Folia Microbiol (Praha)       Date:  2012-09-06       Impact factor: 2.099

10.  GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS.

Authors:  Iman Ramzy; Hassan Elgarem; Iman Hamza; Doaa Ghaith; Tamer Elbaz; Waleed Elhosary; Gehan Mostafa; Mohammad A Mohey Eldin Elzahry
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-12-08       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.